Omalizumab Injection [Xolair]
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder, Atopy
Trial Timeline
Jan 1, 2021 → Jan 1, 2022
NCT ID
NCT04535817About Omalizumab Injection [Xolair]
Omalizumab Injection [Xolair] is a phase 1 stage product being developed by Novartis for Autism Spectrum Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04535817. Target conditions include Autism Spectrum Disorder, Atopy.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04535817 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Autism Spectrum Disorder